Quest for the right Drug
המוסול בי0 HEMOSOL B0 (CALCIUM CHLORIDE DIHYDRATE, LACTIC ACID, MAGNESIUM CHLORIDE HEXAHYDRATE, SODIUM CARBONATE HYDROGEN, SODIUM CHLORIDE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
לשימוש עם מכשירי המודיאליזה : FOR USE WITH HEMODIALYSIS MACHINES
צורת מינון:
תמיסה להמופילטרציה : SOLUTION FOR HAEMOFILTRATION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Special Warning : אזהרת שימוש
4.4 Special warnings and precautions for use Warnings: The substitution solution HEMOSOL B0 is potassium-free. The serum potassium concentration must be monitored before and during hemofiltration and/or hemodialysis. The electrolyte solution must be mixed with the buffer solution before use to obtain the final solution suitable for haemofiltration/haemodiafiltration/continuous haemodialysis. Use only with appropriate extracorporeal renal replacement equipment. Because the solution contains no glucose, administration may lead to hypoglycemia. Blood glucose levels should be monitored regularly. HEMOSOL B0 contains hydrogen carbonate (bicarbonate), and lactate (a hydrogen carbonate precursor) which can influence the patient’s acid–base balance. If metabolic alkalosis develops or worsens during therapy with the solution, the administration rate may need to be decreased, or the administration stopped. The use of contaminated haemofiltration solution may cause sepsis, shock and fatal conditions. Precautions for use: HEMOSOL B0 may be warmed to 37°C to enhance patient comfort. Warming of the solution prior to use should be done before reconstitution with dry heat only. Solutions should not be heated in water or in a microwave oven. The solution should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer unless the solution is clear and the seal is intact. Before and during treatment, electrolyte and acid-base balance should be closely monitored throughout the procedure. Phosphate up to 1.2 mmol/L may be added to the solution. If potassium phosphate is added, the total potassium concentration should not exceed 4 mEq/L (4 mmol/L). Potassium supplement might be necessary. The patient’s hemodynamic status and fluid balance should be monitored throughout the procedure and corrected as needed. Paediatric population: There are no specific warnings and precautions when using this medicine for children.
Effects on Driving
4.7 Effects on ability to drive and use machines Not relevant
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
רישום
129 26 30751 00
מחיר
0 ₪
מידע נוסף